Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Lymphoid 1CNS 1

Conditions

Solitary Fibrous Tumors 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Granuloma, Plasma Cell 1Glioma 1Glioblastoma 1

Interventions

Magnetic Resonance Spectroscopy 8X-Rays 7Specimen Handling 7Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6Biopsy 5ulixertinib 3trametinib 3palbociclib 3larotrectinib 3erdafitinib 3Temozolomide 3tipifarnib 2tazemetostat 2selpercatinib 2olaparib 2ivosidenib 2ensartinib 2dabrafenib 2Vemurafenib 2Topotecan 2Paclitaxel 2Nivolumab 2Lomustine 2LY3023414 2Gemcitabine 2Filgrastim 2varlilumab 1trastuzumab biosimilar HLX02 1sonidegib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × Capsules × Lymphoid × Clear all
NCT04094610 2025-11-19

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
75 enrolled
CNSLymphoidPlasma cellSarcoma

Glioblastoma, Glioma, Granuloma, Plasma Cell, Lymphoma, Neoplasm Metastasis, Sarcoma, Lymphoma, Large-Cell, Anaplastic, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡